2 completed, 2 terminated. 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Completed 2, Terminated 2 |
Follow Revlimid: new trials by email Literature Review of Revlimid trials Research Report on Revlimid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) Thalidomide, Lenalidomide, Questionnaires - Myeloma | Not applicable | Terminated | M.D. Anderson Cancer Center | 10 | 2014-01-01 | 2019-04-29 |
| Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia lenalidomide, laboratory biomarker analysis, lymph node biopsy - B-cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Not applicable | Terminated | Roswell Park Cancer Institute | 8 | 2010-01-01 | 2016-06-30 |
| Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma Azacitidine - Multiple Myeloma | Not applicable | Completed | Virginia Commonwealth University | 17 | 2010-01-01 | 2018-06-26 |
| A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis Lenalidomide, Melphalan, Dexamethasone - Leukemia, Amyloidosis | Not applicable | Completed | Stanford University | 25 | 2009-04-01 | 2017-03-22 |
Multiple Myeloma (2) · Amyloidosis (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Neoplasms, Plasma Cell (1)
M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1) · Stanford University (1) · Virginia Commonwealth University (1)
United States (4)
Amir A. Toor, MD (1) · Myron Czuczman (1) · Qaiser Bashir, MD (1) · Stanley L Schrier, MD (1)
P30CA016059 (1)